FDA Extends Review Period for TransCon CNP to February 28, 2026

Ascendis Pharma's FDA review period for TransCon CNP (navepegritide) for children with achondroplasia has been extended by three months to February 28, 2026, due to a major amendment to the NDA. The company has responded to all outstanding requests from the FDA and is committed to working diligently to finalize elements of the post-marketing requirement. Ascendis aims to bring this innovative therapy to patients in the US as soon as possible.